Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections, a Triple Arm Study
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Nepafenac (Primary)
- Indications Injection site pain; Ocular pain
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Apr 2018 Status changed from recruiting to completed.
- 23 Feb 2018 Planned primary completion date changed from 15 Feb 2018 to 28 Feb 2018.